hERG IC50:Cmax比值预测药物诱发尖端扭转型室速风险的验证与临床效用:一项Meta分析
该Meta分析纳入抗组胺药、氟喹诺酮类和抗精神病药,验证hERG IC50与游离药物峰浓度比值(hERG IC50:Cmax)与TdP发生率的相关性。结果显示该比值与TdP风险相关(0.312;95%CI 0.205-0.476,p<0.0001),比值80对应RR 1.0,支持其用于临床药物选择时评估TdP风险。
要点
- hERG IC50:Cmax比值与TdP发生率显著相关,比值80对应RR 1.0。
- 奥氮平RR与氯雷他定相当,齐拉西酮与环丙沙星相当。
- RR大于50的药物包括阿司咪唑、利培酮、氟哌啶醇和硫利达嗪。
核心结论
- hERG IC50:Cmax比值与可疑药物的TdP发生率相关,支持其用于TdP风险关注时的临床药物选择决策。
研究设计与样本
- Meta分析,检索Medline(1966年至2017年3月)获取抗组胺药、氟喹诺酮类和抗精神病药的hERG IC50与Cmax值,并识别药物诱导的TdP病例。
- TdP病例纳入标准为提供显示QTc延长伴TdP的心电图描记且血清钾、钙、镁正常,排除既往心律紊乱及药物相互作用病例。
- 采用观察性研究Meta分析流行病学清单由两名作者提取数据,药物暴露量由制造商报告的年收入估算。
主要发现
- hERG IC50:Cmax比值与TdP风险相关(0.312;95%CI 0.205-0.476,p<0.0001),比值80对应RR 1.0。
- 奥氮平的RR与氯雷他定相当,齐拉西酮与环丙沙星相当。
- RR大于50的药物包括阿司咪唑、利培酮、氟哌啶醇和硫利达嗪。
关键数值与推荐
- 低风险药物定义为hERG IC50:Cmax比值对应每1亿次暴露中TdP事件概率小于5%(RR 1.0)。
- hERG IC50:Cmax比值80对应RR 1.0。
临床怎么用
- 在关注TdP风险的药物选择场景中,可参考hERG IC50:Cmax比值辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Use of the QT interval corrected for heart rate (QTc) on the electrocardiogram (ECG) to predict torsades de pointes (TdP) risk from culprit drugs is neither sensitive nor specific. The ratio of the half-maximum inhibitory concentration of the hERG channel (hERG IC50) to the peak serum concentration of unbound drug (Cmax ) is used during drug development to screen out chemical entities likely to cause TdP. PURPOSE: To validate the use of the hERG IC50:Cmax ratio to predict TdP risk from a culprit drug by its correlation with TdP incidence. DATA SOURCES: Medline (between 1966 and March 2017) was accessed for hERG IC50 and Cmax values from the antihistamine, fluoroquinolone, and antipsychotic classes to identify cases of drug-induced TdP. Exposure to a culprit drug was estimated from annual revenues reported by the manufacturer. STUDY SELECTION: Inclusion criteria for TdP cases were provision of an ECG tracing that demonstrated QTc prolongation with TdP and normal serum values of potassium, calcium, and magnesium. Cases reported in patients with a prior rhythm disturbance and those involving a drug interaction were excluded. DATA EXTRACTION AND SYNTHESIS: The Meta-Analysis of Observational Studies in Epidemiology checklist was used for epidemiological data extraction by two authors. MAIN OUTCOME AND MEASURE: Negligible risk drugs were defined by an hERG IC50:Cmax ratio that correlated with less than a 5% chance of one TdP event for every 100 million exposures (relative risk [RR] 1.0). RESULTS: The hERG IC50:Cmax ratio correlated with TdP risk (0.312; 95% confidence interval 0.205-0.476, p<0.0001), a ratio of 80 (RR 1.0). The RR from olanzapine is on par with loratadine; ziprasidone is comparable with ciprofloxacin. Drugs with an RR greater than 50 include astemizole, risperidone, haloperidol, and thioridazine. CONCLUSIONS: The hERG IC50:Cmax ratio was correlated with TdP incidence for culprit drugs. This validation provides support for the potential use of the hERG IC50:Cmax ratio for clinical decision making in instances of drug selection where TdP risk is a concern.
引用
- Lehmann DF, Eggleston WD, Wang D, et al. Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis. Pharmacotherapy. 2018. PMID: 29380488. doi:10.1002/phar.2087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。